These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 38427314)

  • 1. Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review.
    Pishdad R; Auwaerter PG; Kalyani RR
    Curr Diab Rep; 2024 May; 24(5):108-117. PubMed ID: 38427314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea.
    Yang H; Choi E; Park E; Na E; Chung SY; Kim B; Han SY
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00910. PubMed ID: 35005849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors.
    Rizzi M; Trevisan R
    Nutr Metab Cardiovasc Dis; 2016 Nov; 26(11):963-970. PubMed ID: 27514605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter-2 Inhibitors.
    Benjamin T; Schumacher C
    Pharmacotherapy; 2020 Oct; 40(10):1002-1011. PubMed ID: 32866995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of sodium-glucose cotransporter 2 inhibitor-related genital and urinary tract infections via electronic medical record-based common data model.
    Ko S; Kim H; Shinn J; Byeon SJ; Choi JH; Kim HS
    J Clin Pharm Ther; 2021 Aug; 46(4):975-983. PubMed ID: 33565150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
    Puckrin R; Saltiel MP; Reynier P; Azoulay L; Yu OHY; Filion KB
    Acta Diabetol; 2018 May; 55(5):503-514. PubMed ID: 29484489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System.
    Yang T; Zhou Y; Cui Y
    Expert Opin Drug Saf; 2024 Aug; 23(8):1035-1040. PubMed ID: 38009230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
    Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
    Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
    Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Liu J; Li L; Li S; Jia P; Deng K; Chen W; Sun X
    Sci Rep; 2017 Jun; 7(1):2824. PubMed ID: 28588220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week.
    Kittipibul V; Cox ZL; Chesdachai S; Fiuzat M; Lindenfeld J; Mentz RJ
    J Am Coll Cardiol; 2024 Apr; 83(16):1568-1578. PubMed ID: 38631776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?-a cross sectional analysis of a nationwide Japanese claims database.
    Anan G; Kikuchi D; Omae K; Hirose T; Okada K; Mori T
    Endocr J; 2023 Nov; 70(11):1103-1107. PubMed ID: 37673640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.
    Bhosle D; Indurkar S; Quadri U; Chandekar B
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of genitourinary infection in diabetic patients treated with SGLT 2 inhibitors.
    Shrikrishna A; Archana B
    Afr Health Sci; 2023 Mar; 23(1):270-275. PubMed ID: 37545909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes.
    Tanrıverdi M; Baştemir M; Demirbakan H; Ünalan A; Türkmen M; Tanrıverdi GÖ
    BMC Endocr Disord; 2023 Oct; 23(1):211. PubMed ID: 37789335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic pyuria and bacteriuria are not risk factors for urinary tract infection in women with type 2 diabetes mellitus initiated SGLT2 inhibitors.
    Akkuş E; Gökçay Canpolat A; Demir Ö; Çorapçıoğlu D; Şahin M
    Int Urol Nephrol; 2024 Mar; 56(3):1165-1172. PubMed ID: 37715859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urinary tract infection caused by Candida while using an SGLT-2 inhibitor].
    Zeelenberg AM; van der Wielen GJ; Beishuizen ED; Hetem DJ
    Ned Tijdschr Geneeskd; 2023 Aug; 167():. PubMed ID: 37609918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials.
    Adeghate E; Mohsin S; Adi F; Ahmed F; Yahya A; Kalász H; Tekes K; Adeghate EA
    Expert Opin Investig Drugs; 2019 Sep; 28(9):811-820. PubMed ID: 31402716
    [No Abstract]   [Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
    Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
    J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.